Orbitofrontal cortex (?)
GABA (only small amount
2.22 Mood stabilizers Comparative profile
Clinical efficacy Side-e ff ec ts Antimanic Anti-dysphoric mania During acute exacerbation During remission phase Anti-MDD Antimanic Anti-MDD Anti-rapid cycling Leukocytosis Aplastic anemia; agranulocytosis Thrombocytopenia Thyroid hormones (decreased) Ca2 Hyponatremia Diabetes insipidus Psoriasis Migraine-like/headache Tremor Memory impairment Alopecia Hepatitis; decreased liver functions Ataxia; diplopia Pruritis rash (benign) SLE-like; Stevens–Johnson syndrome Teratogenic Nystagmus Sedation GIT disturbances; diarrhea Pancreatitis Weight gain W W Lithi um Ca rba m azepi n e V alp roate La m ot ri g in e T opi ra m ate
Most effacious in / major capacity for inducing side-effect
Moderate efficacy / moderate capacity for inducing side-effect
Minor efficacy / minor capacity for inducing side-effect
Questionable efficacy / negligible capacity for inducing side-effect
Data insufficient / not well-established Increased / decreased
GIT Gastrointestinal tract MDD Major depressive disorder
SLE Systemic lupus erythematosus W Might worsen existing phenomena
References
1. Nemeroff CB. Recent advances in the neurobiology of depression.
Psychopharmacol Bull 2002 (Summer); 13: 6. 2. Manji HK, Quiroz JA, Sporn J et al.
Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult to treat depression. Biol Psychiatry 2003; 53: 707–742.
3. Zarate CA, Quiroz JA, Payne K et al. Modulators of the glutamatergic system: implications for the development of improvement of improved therapeutics in mood disorders. Psychopharmacol Bull 2002 (Autumn); 4: 35–83.
4. Skolnick P. Antidepressants for the new millennium. Eur J Pharmacol 1999; 375: 31–40.
5. Tran PV, Bymaster FP, McNamara RK et al. Dual monoamine modulation for improved treatment of major depressive disorder. J Clin Psychopharmacol 2003; 23: 78–86. 6. Bodkin JA. Transdermal selegiline in major
depression: a double-blind placebo-
controlled, parallel study in outpatients. Am J Psychiatry 2002; 159: 1869–1875.
7. Thase ME. Achieving remission and managing relapse in depression. J Clin Psychiatry 2003; 64: 3–7.
8. Thase ME, Ninan PT. New goals in the treatment of depression: moving towards recovery. Psychopharmacol Bull 2002; 36: 24–35.
9. Lattanzi L, Dell’Osso L, Cassano P et al. Pramipexole in treatment-resistant depression: a 16-week naturalistic study. Bipolar Disord 2002; 4: 305–314. 10. Izumi T, Inoue T, Kitagawa N et al. Open
pergolide treatemtn of tricyclic and heterocyclic antidepressant-resistant depression. J Affect Disord 2000; 61: 127–132.
11. Perugi G, Toni C, Ruffolo G et al. Adjunctive dopamine agonists in treatment-resistant bipolar II depression: an open case series. Pharmacopsychiatry. 2001; 34: 137–141. 12. Kitamura Y, Taniguchi T, Shimohama S et al.
Neuroprotective mechanisms of antiparkinsonian dopamine D2-receptor
subfamily agonists. Neurochem Res 2003; 28: 1035–1040.
13. Robinson DS. Monoamine oxidase inhibitors: a new generation.
Psychopharmacol Bull 2002 (Summer); 3: 124–138.
14. Trevor R, Olver N, Olver J. New formulations
16. Ostacher MJ, Eisner L, Nierenberg AA. Mirtazapine in the treatment of mood and anxiety disorders. Expert Rev Neurotherap 2003; 3: 425–433.
17. Benkert O, Muller M, Szegedi A. An overview of the clinical efficacy of
mirtazapine. Hum Psychopharmacol 2002; 17: S23–S26.
18. Pallanti S, Quercioli L, Bruscoli M. Response acceleration with mirtazapine augmentation of citalopram in obsessive compulsive disorder patients without comorbid depression; a pilot study. J Clin Psychiatry 2004; 65: 1394–1399.
19. Waugh J, Goa KL. Escitalopram: a review of its use in the management of major depressive and anxiety disorders. CNS Drugs 2003; 17: 343–362.
20. Wengel SP, Burke WJ. Escitalopram: What does it have to offer? Primary Psychiatry 2003; 10: 67–70.
21. Olver JS, Cryan JF, Burrows GD et al.
Pindolol augmentation of antidepressants: a review and rationale. Aust NZ J Psychiatry 2000; 34: 71–79.
22. Elhwuegi AS. Central monoamines and their role in major depression. Prog
Neuropsychopharmacol Biol Psychiatry 2004; 28: 435–451.
23. Dannon PN, Sasson Y, Hirschmann S et al. Pindolol augmentation in treatment resistant obsessive compulsive disorder: a double blind placebo controlled trial. Eur Neuropsychopharmacol 2000; 10: 165–169. 24. Sokolski KN, Conney JC, Brown BJ et al.
Once daily high dose pindolol for SSRI- refractory depression. Psychiatry Res 2004; 15: 125: 81–86.
25. Yamada M, Yasuhara H. Clinical
pharmacology of MAO inhibitors: safety and future. Neurotoxicology 2004; 25: 215–221.
26. Knoll J. ()Deprenyl (selegiline): past, present and future. Neurobiology 2000; 8: 179–199.
27. Wilcock GK, Birks J, Whitehead A et al. The effect of selegiline in the treatment of people with Alzheimer’s disease: a meta- analysis of published trials. Int J Geriatr Psych 2002; 17: 175–183.
28. Grunze H, Kasper S, Goodwin G et al. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorder, Part II: Treatment of Mania. World J Biol Psychiatry 2003; 4: 5–13.
29. Swann AC, Bowdem CL, Calabrese JR et al. Differential effect of number of previous
and manic episodes on response to
treatment. Acta Psychiatr Scand 2000; 101: 444–451.
31. Tohen M, Jacobs TG, Grundy SL et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. 2000; 57: 849.
32. Sachs G, Grossman F, Okamoto A et al. Risperidone plus mood stabilizer versus placebo plus mood stabilizer for acute mania of bipolar disorder: a double-blind comparison of efficacy and safety. Am J Psychiatry 2002, 159: 1146–1154.
33. Tohen M, Zarate CA Jr. Antipsychotic agents and bipolar disorder. J Clin Psychiatry 1998; 59 (Suppl 1): 38–48.
34. Freeman TW, Clothier JL, Pazzaglia P et al. A double-blind comparison of valproate and lithium in the treatment of acute mania. Am J Psychiatry. 1992; 149: 108–111.
35. Swann AC, Bowden CL, Morris D et al. Depression during mania. Treatment response to lithium or divalproex. Arch Gen Psychiatry 1997; 54: 37.
36. Goldberg JF, Garno JL, Leon AC et al. Rapid titration of mood stabilizers predicts remission from mixed or pure mania in bipolar patients. J Clin Psychiatry 1998; 59: 151–158.
37. Benabarre A, Vieta E, Colom F et al.
Treatment of mixed mania with risperidone and mood stabilizers. Can J Psychiatry 2001; 46: 866–867.
38. Whitlock FA, Evans LE. Drugs and depression. Drugs 1978; 15: 53–71.
39. Brunello N, Tascedda F. Cellular mechanism and second messengers: relevance to the psychopharmacology of bipolar disorders. Int J Neuropsychopharmacol 2003; 6: 181–189.
40. Manji HK, Quiroz JA, Sporn J et al. Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult to treat depression. Biol Psychiatry 2003; 53: 707–742.
41. Baldessarini RJ, Tondo L, Hennen J. Lithium treatment and suicide risk in major affective disorders: update and new findings. J Clin Psychiatry 2003; 64(Suppl); 5: 44–52. 42. Moore G, Bebchuk J, Hasanat K et al.
Lithium increases N-acetyl-aspartate in the human brain: in vivo evidence in support of bcl-2’s neurotrophic effects? Biol Psychiatry 2000; 48: 1–8.
43. Moore G, Bebchuk J, Wilds I et al. Lithium therapy increases gray matter volume.
45. Harwood AJ, Agam G. Search for common mechanism of mood stabilizers. Biochem Pharmacol 2003; 66: 179–189.
46. Ambrosio AF, Soares-da-Silva P, Carvalho CM et al. Mechanism of action of
carbamazepine and its derivatives,
oxcarbazepine, BIA 2-093, and BIA 2-024*. Neurochem Res 2002; 27: 121–130.
47. Harwood AJ, Agam G. Search for a common mechanism of mood stabilizers. Biochem Pharmacol 2003; 66: 179–189.
48. Li X, Ketter TA, Frye MA. Synaptic, intracellular and neuroprotective
mechanisms of anticonvulsants: Are they relevant for the treatment of bipolar disorder? J Affect Disord 2002; 69: 1–14. 49. Manji HK, Moore GJ, Rajkowska G et al.
Neuroplasticity and cellular resilience in mood disorders. Mol Psychiatry 2000; 5: 578–593.
50. Gray NA, Zhou R, Du J et al. The use of mood stabilizers as plasticity enhancers in the treatment of neuropsychiatric disorders. J Clin Psychiatry 2003; 64(Suppl): 3–17. 51. Drevets WC. Neuroimaging and
neuropathological studies of depression: implications for the cognitive-emotional features of mood disorders. Curr Opin Neurobiol 2001; 11: 240–249.
52. Owens MJ, Nemeroff CB. Pharmacology of valproate. Psychopharmacol Bull 2003; 37(Suppl 2): 17–24.
53. Topamax package insert. Raritan, NJ: Ortho-McNeill Pharmaceutical, 2000. 54. Suppes T. Review of the use of topiramate
for treatment of bipolar disorder. J Clin Psychopharmacol 2002; 22: 599–609. 55. McElroy SL, Suppes T, Keck PE et al. Open-
label adjunctive Topiramate in the treatment of bipolar disorder. Biol Psychiatry. 2000; 47: 1025–1033.
56. Marcotte D. Use of topiramate, a new anti- epileptic, as a mood stabilizer. J Affect Disord 1998; 50: 245–251.
57. Calabrese JR, Keck PE Jr, McElroy SL et al. A pilot study of topiramate as monotherapy in the treatment of acute mania. J Clin
Psychopharmacol 2001; 21: 340–342. 58. Grunze HC, Norman C, Langosch J et al.
Antimanic efficacy of topiramate in 11 patients in open trial with an on–off–on design. J Clin Psychiatry 2001; 62: 464–468. 59. Gupta S, Masand PS, Frank B et al.
Topiramate in bipolar and schizoaffective disorder: mood stabilizing properties in treatment refractory patients. XXII Collegium Internationale
61. Suppes T. Review of the use of topiramate for treatment of bipolar disorder. J Clin Psychopharmacol 2002; 22: 599–609. 62. Kusumakar V, Yatham L, O’Donovan C et al.
Topiramate in rapid cycling bipolar woman. 152nd Annual Meeting of the American Psychiatric Association, Washington, DC, May 1999.
63. Gilliam FG, Veloso F. Tolerability of
topiramate as monotherapy in patients with recently diagnosed partial epilepsy. Epilepsia 1998; 39(Suppl 6): 56.
64. Privitera MD, Brodie MJ, Neto W et al. Topiramate vs. investigator choice of
carbamazepine or valproate as monotherapy in newly diagnosed epilepsy. Epilepsia 2000; 41: 93–94.
65. Wasserstein AG, Rak I, Reife RA. Nephrolithiasis during treatment with topiramate. Epilepsia 1995; 36(Suppl 3): S153.
66. Aldenkamp AP, Baker G, Mulder OG et al. A multicenter randomized clinical study to evaluate the effect on cognitive function of topiramate compared with valproate as add- on therapy to carbamazepine in patients with partial-onset seizures. Epilepsia 2000; 41: 1167–1178.
67. Ketter TA, Manji HK and Post RM. Potential mechanisms of action of lamotrigine in the treatment of bipolar disorder. J Clin
Psychopharmacol 2003; 23: 484–495.
68. Calabrese JR, Bowden CL, Sachs GS et al. Lamictal 602 Study Group. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. J Clin Psychiatry 1999; 60: 79–88.
69. Calabrese JR, Suppes T, Bowden CL et al. Lamictal 614 Study Group. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. J Clin Psychiatry 2000; 61: 841–850.
70. Frey MA, Ketter TA, Kimbrell TA et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 2002; 22: 607–614.
71. Ketter TA, Calabrese JR. Stabilization of mood from below versus above baseline in bipolar disorder: a new nomenclature. J Clin Psychiatry 2002; 63: 146–151.
72. Bowden CL. Acute and maintenance treatment with mood stabilizers. Int J Neuropsychopharmacol 2003; 6: 269–275.
73. Xie X, Hagan RM. Cellular and molecular actions of lamotrigine: possible mechanisms of efficacy in bipolar disorder.
Neuropsychobiology 1998; 38: 119–130. 74. Goldsmith DR, Wagstaff AJ, Ibbotson et al.
Spotlight on lamotrigine in bipolar disorder. Int J Neuropsychopharmacol 2003; 6: 239–275.